Equity Vii L.P. Spectrum Sells 10,677 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) Stock

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction on Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total value of $51,249.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.

Equity Vii L.P. Spectrum also recently made the following trade(s):

• On Friday, June 6th, Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock. The shares were sold at an average price of $4.09, for a total value of $43,668.93.

GoodRx Stock Performance

Shares of NASDAQ GDRX traded down $0.29 during midday trading on Friday, hitting $4.76. The company's stock had a trading volume of 2,817,927 shares, compared to its average volume of 1,427,698. The company has a debt-to-equity ratio of 0.74, a quick ratio of 5.23 and a current ratio of 5.23. The firm's fifty day moving average price is $4.35 and its 200-day moving average price is $4.52. The firm has a market cap of $1.70 billion, a P/E ratio of 59.49, a P/E/G ratio of 2.09 and a beta of 1.24. GoodRx Holdings, Inc. has a 1-year low of $3.68 and a 1-year high of $9.26.

GoodRx (NASDAQ:GDRX - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. GoodRx had a net margin of 3.57% and a return on equity of 7.85%. The business had revenue of $202.97 million for the quarter, compared to the consensus estimate of $202.25 million. During the same period in the previous year, the firm earned $0.08 EPS. The business's revenue for the quarter was up 2.6% on a year-over-year basis. On average, sell-side analysts forecast that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On GoodRx

Several large investors have recently bought and sold shares of the stock. National Bank of Canada FI increased its position in GoodRx by 34.9% in the 4th quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock valued at $39,000 after acquiring an additional 2,151 shares in the last quarter. Hohimer Wealth Management LLC raised its holdings in shares of GoodRx by 8.2% in the first quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company's stock valued at $155,000 after purchasing an additional 2,658 shares during the last quarter. SBI Securities Co. Ltd. raised its holdings in shares of GoodRx by 13.8% in the first quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company's stock valued at $100,000 after purchasing an additional 2,748 shares during the last quarter. Gotham Asset Management LLC increased its holdings in GoodRx by 31.0% during the fourth quarter. Gotham Asset Management LLC now owns 17,677 shares of the company's stock worth $82,000 after buying an additional 4,182 shares during the last quarter. Finally, Swiss National Bank increased its stake in shares of GoodRx by 4.1% during the 4th quarter. Swiss National Bank now owns 161,400 shares of the company's stock worth $751,000 after purchasing an additional 6,400 shares during the last quarter. 63.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on GDRX shares. Truist Financial cut their price target on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research note on Thursday, April 10th. The Goldman Sachs Group cut their price objective on GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Wells Fargo & Company dropped their price target on GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Finally, UBS Group decreased their price objective on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Five equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $6.55.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.